CONMED Corp. Stock Plummets to New 52-Week Low of $31.86

CONMED Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 31.86 as of June 17, 2026. This marks a significant decline for the company, which has seen its stock price decrease by 56.87% over the past year, contrasting sharply with the S&P 500's performance of 24.03% during the same period. The company's market capitalization stands at USD 1,138 million, and it currently has a price-to-earnings (P/E) ratio of 17.00. Despite a high dividend yield of 108.09%, CONMED has faced challenges in maintaining growth, with a reported net profit of USD 27.05 million reflecting a decline of 45.97%. Additionally, the company's return on equity is at 6.65%, and its price-to-book ratio is 1.10. The stock's previous 52-week high was USD 56.64, indicating a substantial drop in value. This performance highlights the difficulties CONMED Corp. is experiencing in both the short and long term, as it continues to navigate a competitive market landscape.